Rituximab therapy for childhood Evans syndrome

Haematologica

Volumn 92, Issue 12, 2007, Pages 1691-1694

  Bader Meunier, Brigitte ^a   Aladjidi, Nathalie ^b   Bellmann, Françoise ^c   Monpoux, Fabrice ^d   Nelken, Brigitte ^e   Robert, Alain ^f   Armari Alla, Corinne ^g   Picard, Capucine ^h   Ledeist, Françoise ⁱ   Munzer, Martine ^j   Yacouben, Karima ^a   Bertrand, Yves ^k   Pariente, Antoine ^l   Chaussé, Arnaud ^b   Perel, Yves ^b   Leverger, Guy ^c  

^a HÔPITAL ROBERT DEBRÉ   (France)

^b HÔPITAL PELLEGRIN   (France)

^c ARMAND TROUSSEAU HOSPITAL   (France)

^d CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^e LILLE UNIVERSITY HOSPITAL   (France)

^f HÔPITAL DES ENFANTS   (France)

^g CHU La Tronche and University   (France)

^h HÔPITAL NECKER ENFANTS MALADES   (France)

ⁱ UNIVERSITY OF MONTREAL   (Canada)

^j AMERICAN MEMORIAL HOSPITAL   (France)

^k HÔPITAL DEBROUSSE   (France)

^l UNIVERSITÉ DE BORDEAUX   (France)

more..

Author keywords

Autoimmune hemolytic anemia; Autoimmune thrombocytopenic purpura; Children; Evans syndrome; Rituximab.

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DANAZOL; DIPHENHYDRAMINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; PARACETAMOL; PREDNISONE; RITUXIMAB; STEROID; VINCRISTINE;

ADOLESCENT; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPENIA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; INFANT; MALE; MONOTHERAPY; REMISSION; RETROSPECTIVE STUDY; STEROID THERAPY;

EID: 37049031252     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.11540     Document Type: Article

References (20)

1. Evans RS, Takahashi K, Duane RT. Primary thrombocytopenic purpura and acquired haemolytic anemia. Arch Int Med 1951;87:48-65.
2. Pui CH, Wilimas J, Wang W. Evans syndrome in childhood. J Pediatr 1980;97:754-8.
3. Mathew P, Chen G, Wang W. Evans syndrome: Results of a national survey. Pediatr Hematol Oncol 1997;19:433-7.
4. Suvasan S, Warrier I, Ravindranath Y. The spectrum of Evans' syndrome. Arch Dis Child 1997;77:245-8.
5. Blouin P, Auvrignon A, Pagnier A, Thuret I, Antoni G, Bader-Meunier et al. Evans' syndrome: a retrospective study from the ship (French Society of Pediatric Hematology and Immunology) (36 cases). Arch Pediatr 2005;12:1600-7.
6. Norton A, Roberts I. Management of Evans syndrome. Br J Haematol 2005;132:125-37.
7. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum 2003;48:1484-92.
8. Zecca M, Nobili B, Ramenghi U, Perrotta S, Amendola G, Rosito P, et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children, Blood 2003;101:3857-61.
9. Quartier P, Brethon B, Phillippet P, Landman-Parker J, Le Deist F, Fischer A. Treatment of childhood autoimmune haemolytic anemia with rituximab, Lancet 2001;358:1511-3.
10. Wang J, Wiley JM, Luddy R, Greenberg J, Feuerstein MA, Bussel JB. Chronic immune thrombocytopenic purpura in children: Assessment of rituximab treatment. J Pediatr 2005;146:217-21.
11. Bennett CM, Rogers ZR, Kinnamon DD, Bussel JB, Mahoney DH, Abshire TC, et al. Prospective phase study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood 2006;107:2639-42.
12. Jubinsky PT, Rashid N. Successful treatment of a patient with mixed warm and cold antibody mediated Evans syndrome and glucose intolerance. Pediatt Blood Cancer 2005;45:347-50.
13. Smith KG, Jones RB, Burns SM, Jayne DR. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and retreatment. Arthr Rheum 2006; 54:2970-82.
14. Gottenberg JE, Guillevin L, Lambotte O, Combe B, Allanore Y, Cantagrel A, et al. Tolerance and short-term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005;64:913-20.
15. Larrar S, Guitton C, Willems M, Bader-Meunier B. Severe hematological side effects following rituximab therapy in children. Haematologica 2006;91 [Suppl 8]:ECR36.
16. Marks SD, Patey S, Brogan PA, Hasson N, Pilkington C, Woo P, Tullus K. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum 2005;52:3168-74.
17. Willems M, Haddad E, Niaudet P, Kone-Paut I, Bensman A, Cochat P, et al. Rituximab therapy for childhood-onset systemic lupus erythematosus. J Pediatr 2006;148:623-7.
18. Quartier P, Tournilhac O, Archimbaud C, Lazaro L, Chaleteix C, Millet P, et al. Enteroviral meningoencephalitis after anti-CD20 (Rituximab) treatment. Clin Infect Dis 2003;36:e47-e9.
19. Anolik JH, Campbell D, Felgar R, Young F, Sanz I, Rosenblatt J, et al. The relationship of FcIIIa genotype to degree of Bcell depletion by rituximab in the treatment of SLE. Arthritis Rheum 2003;48:455-9.
20. + cells by rituximab. Blood 2003;101:1071-9.